Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROCKET-Horizon: Rocatinlimab Monotherapy in Moderate-to-severe Atopic Dermatitis
jRCT2031230004Phase 3Completed
- Sponsor
- Amgen
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Rocatinlimab Q4W with Placebo Q4W (2 arms). Primary endpoints: vIGA-AD 0/1 with ≥2-point reduction at Week 24 and EASI 75 at Week 24. Started Mar 2023; status: completed.
02
Drugs
rocatinlimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031230004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230004.